Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — Q4 FY2024 Earnings Presentation
27 slides from Camlin Fine Sciences's earnings presentation, May 20, 2024
Slide 1: Stock exchange intimation letter
May 20, 2024 To, To, BSE Limited, Listing Department, 25, P. J. Towers, National Stock Exchange of India Ltd., Dalal Street, Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai‐ 400051 Ref: Company Scrip Code: 532834 Ref: Symbol: CAMLINFINE || Series: EQ Sub: Intimation purs
Slide 2: Investor Presentation – May 2024
Investor Presentation – May 2024
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Camlin Fine Sciences Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Q4 & FY24 Performance Highlights
Q4 & FY24 Performance Highlights 3
Slide 5: Q4 & FY24 Operational Highlights
Q4 & FY24 Operational Highlights Key Highlights › Total Revenue stood at Rs. 16,131 mn in FY24, a 4% drop as compared to FY23. Company reported loss of Rs. 1,049 mn in FY24 for the following reasons, ▪ Subdued revenue from Aroma business and closure of CFS Europe facility in August 2023 has dragged
Slide 6: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. In Mn) Q4 FY23 Q4 FY24 FY23 FY24 Revenue from Operation 4,267.1 4,016.9 16,815.6 16,130.6 Raw material consumption 2,109.9 2,248.2 8,132.3 8,768.1 Due to an unprecedented reduction in prices of Catechol and Vanillin, value of inventories as on Wr
Slide 7: Q4 & FY24 Operational Highlights
Q4 & FY24 Operational Highlights Revenue (Rs. In Mn) EBITDA* (Rs. In Mn) PAT (Rs. In Mn) 4,267 3,859 4,017 557 35 325 -143 45 Q4FY23 Q3FY24 Q4FY24 Q4FY23 Q3FY24 Q4FY24 -818 Q4FY23 Q3FY24 Q4FY24 16,816 16,131 2,131 398 1,134 FY23 FY24 FY23 FY24 -1,049 FY23 FY24 On Consolidated Basis *EBITDA is adjust
Slide 8: Operational Revenue Break-up
Operational Revenue Break-up Shelf-Life Extension (Rs. In Mn) Blends (Rs. In Mn) Total Shelf-Life Solution (Rs. In Mn) 4,576 7,288 11,400 4,111 9,679 5,103 1,058 1,017 1,843 2,349 2,860 1,291 Q4FY23 Q4FY24 FY23 FY24 Q4FY23 Q4FY24 FY23 FY24 Q4FY23 Q4FY24 FY23 FY24 Performance Chemicals (Rs. In Mn) Ar
Slide 9: Regional Highlights
Regional Highlights CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 7,894 7,733 4,822 4,883 3,533 2,271 2,182 2,203 1,217 849 1,015 413 Q4FY23 Q4FY24 FY23 FY24 Q4FY23 Q4FY24 FY23 FY24 Q4FY23 Q4FY24 FY23 FY24 CFS Brazil (Rs. In Mn) CFS North America (Rs. In Mn) 1.504 2,552 1.129 8
Slide 10: Standalone Profit & Loss Statement
Standalone Profit & Loss Statement Particulars (Rs. In Mn) Q4 FY23 Q4 FY24 FY23 FY24 Revenue from Operation 2,181.6 2,203.3 7,894.4 7,732.6 Raw material consumption 974.6 1,282.0 3,656.9 4,068.6 Write down of Inventory 0.0 368.1 0.0 368.1 Employee Cost 165.1 165.4 597.1 659.5 Other expenses 698.9 64
Slide 11: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (Rs. In Mn) Mar - 23 Mar – 24 Particulars (Rs. In Mn) Mar - 23 Mar – 24 Equity Non-Current assets Equity Share Capital 157.1 167.5 Property, Plant and Equipment 7,525.2 7,122.4 Other Equity 8,036.6 8,480.0 Capital Work-In-Progress 408.4 455.6 Minority interest
Slide 12: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. In mn) Mar – 23 Mar – 24 Net Profit Before Tax 803.8 -992.4 Adjustments for: Non-Cash Items / Other Investment or Financial Items 1295.0 2,540.9 Operating profit before working capital changes 2,098.8 1,548.4 Changes in working capital 710.9 1,865.2
Slide 13: Touching Billions of Lives Daily
Touching Billions of Lives Daily Vertical Integration | Green Chemistry | R&D | Innovative Solutions
Slide 14: Company Overview
Company Overview 1,250+ Base of Satisfied Customers Worldwide 100 + Range of Diversified Products 61,000 + MT Led by Integrated Global Among Global Leaders Production Capacity Catering Diverse Industries In the Manufacturing of Antioxidants Food and Beverage Animal Nutrition Pet Food Preferred Partn
Slide 15: Global Footprint
Global Footprint Capacity (in MT) 9 5 31,000 12,000 Global Manufacturing Application CFS Europe SpA, Italy Camlin Fine Sciences, India Facilities Laboratories 80+ 2 6,000 CFS do Brasil 12,000 CFS Dresen, Mexico Countries Global R&D Centres Sales Network CFA Europe SpA, Italy, CFS has multiple operat
Slide 16: Product Highlights
Product Highlights FY24 Sales Mix% Key Products End User Industries Key Brands › TBHQ › Pet Food › Animal Feed Mills Straights 26% › BHA › Livestock Nutrition › Biodiesel › Ascorbyl palmitate (ASP) › Food & Beverages › Aquaculture › Fish Meal › Rendering Shelf-Life Solutions › 200+ custom formulatio
Slide 17: Vertical Integration | Green Chemistry | R&D | Innovative Solutions
Vertical Integration | Green Chemistry | R&D | Innovative Solutions From Source, to Quality Solutions • Efforts in both organic and inorganic expansions, showcases company’s commitment to fortifying position in the market Backward Integrated through Italy & Dahej • Strategic focus on captive consumpt
Slide 18: Manufactured In-house
Integration Chain Phenol Hydroquinone Diphenols Catechol Manufactured In-house Performance Performance Shelf Life Solutions Chemicals Aroma Ingredients Chemicals Ascorbyl Palmitate1 TBHQ MEHQ Guaiacol Guethol BHA Other derivatives of HQ Veratrole Vanillin Other derivatives of Blends Ethyl Vanillin C
Slide 19: ESG
ESG As a responsible corporate, CFS understand the importance of Environmental, Social and Governance (ESG) practices in conducting business ethically. Company’s commitment to ESG extends beyond compliance with regulations and laws. Company aims to minimize environmental impact, promote social respo
Slide 20: Board of Directors
Board of Directors Name Profile Ashish Dandekar › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, research Chairman & Managing Director & development, product development, and marketing › Holds a BA in Economics an
Slide 21: Senior Management Team
Senior Management Team Name › Profile Ashish Dandekar › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information systems, Chairman & Managing Director research & development, product development, and marketing › Holds a BA in Econom
Slide 22: Way Forward
Way Forward Shelf-Life Solutions Performance Chemicals Aroma Ingredients Health and Wellness • Aim to expand Diphenol chain, • Introduce specialized and customized • Maintaining market leadership for specifically focusing on expanding products within the vanillin range, catering Antioxidants • Impro
Slide 23: Historical Financial Highlights
Historical Financial Highlights 22
Slide 24: Historical Financial Highlights
Historical Financial Highlights Margin Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) 12.5% 15.3% 10.8% 12.7% 7.0% 2.8% 5.5% 4.3% 2.4% -6.5% 16,816 16,131 14,121 11,871 2,131 654 604 10,168 1,819 298 398 1,528 1,307 1,134 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 -1,049 FY20 FY21 FY2
Slide 25: Operational Revenue Break-Up
Operational Revenue Break-Up Shelf-Life Extension (Rs. In Mn) Blends (Rs. In Mn) Total Shelf-Life Solution (Rs. In Mn) 11,400 9,679 4,576 7,288 4,111 7,980 3,812 5,103 6,171 2,860 4,168 5,516 2,381 3,135 3,311 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 Performance Che
Slide 26: Regional Highlights
Regional Highlights CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 7,894 7,733 4,822 4,883 6,855 4,395 5,798 6,000 3,533 3,762 3,198 3,091 2,571 2,735 2,271 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 CFS Brazil (Rs. In Mn) CFS Wanglong (Rs. In Mn)
Slide 27: Thank You!
Thank You! Camlin Fine Sciences Ltd. CIN – L74100MH1993PLCO75361 Mr. Santosh Parab- CFO Email – santosh.parab@camlinfs.com www.camlinfs.com http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Shrikant Sangani / Ms. Shaily Patwa Email – shrik
Camlin Fine Sciences — Q4 FY2024 Earnings Presentation on 6ix